<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.2" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJMABHR</journal-id>
<journal-title-group><journal-title>International Journal of Medical and All Body Health Research</journal-title><abbrev-journal-title>IJMABHR</abbrev-journal-title></journal-title-group>
<issn pub-type="epub">2582-8940</issn>
<publisher><publisher-name>Anfo Publication House</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">455</article-id>
<article-id pub-id-type="doi">10.54660/IJMBHR.2026.7.1.188-194</article-id>
<title-group><article-title>Engineering Nanotherapeutics to Overcome Multidrug-Resistant Pathogens: From Mechanistic Insights to Clinical Translation</article-title></title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><name><surname>Thamer</surname><given-names>Roaa A</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<aff id="aff1"><label>1</label>Medical Laboratory Techniques Department, Mosul Medical Technical Institute, Northern Technical University, Mosul 41001, Iraq</aff>
</contrib-group>
<pub-date publication-format="electronic" date-type="pub"><day>14</day><month>02</month><year>2026</year></pub-date>
<volume>7</volume>
<issue>1</issue>
<fpage>188</fpage>
<lpage>194</lpage>
<history>
<date date-type="received"><day>11</day><month>12</month><year>2025</year></date>
<date date-type="accepted"><day>12</day><month>01</month><year>2026</year></date>
</history>
<permissions><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-sa/4.0/?utm"><license-p>CC BY-NC-SA 4.0</license-p></license></permissions>
<self-uri xlink:href="https://www.allmedicaljournal.com/article/455/engineering-nanotherapeutics-to-overcome-multidrug-resistant-pathogens-from-mechanistic-insights-to"/>
<self-uri content-type="pdf" xlink:href="https://www.allmedicaljournal.com/article/455/download"/>
<abstract><p>This scientific article addresses a growing and serious problem that threatens global public health, namely antimicrobial resistance (AMR) and multidrug-resistant bacteria (MDR). Statistics suggest that this problem could cause 10 million deaths per year by 2050 if effective solutions are not developed. Conventional antibiotics are increasingly failing to treat this infection due to the bacteria&quot;s sophisticated resistance mechanisms, such as the formation of biofilms that protect them, the secretion of antibiotic-disrupting enzymes, and the use of Efflux pumps to expel the antibiotic out of the cell.
The article reviews the innovative solutions offered by the field of nanotherapeutics to combat these challenges. This technology not only improves the delivery of conventional medicines, but also goes beyond designing smart platforms that can overcome bacterial resistance mechanisms in multiple ways:
Nano delivery Platforms: The use of nanoparticles (such as polymers or lipids) to carry antibiotics, protecting them from degradation, improving their penetration into bacterial biofilms, and prolonging their stay at the site of infection.
Smart Targeting: The design of nanovectors to selectively target bacteria (via passive or active targeting) or to release their load from the drug in response to specific signals in the infection environment (e.g., pH), increasing efficacy and reducing side effects.
Innovative Mechanisms: Use advanced strategies such as &quot;nanodecoys&quot; that mimic human cell receptors to trick and bind bacteria, or modulate the body&quot;s immune response to fight infection more effectively.
Synergistic Effect: Combining nanoparticles (such as metals) with conventional antibiotics to enhance their bacteria-killing effect across multiple and sequential mechanisms of action.
 </p></abstract>
<kwd-group kwd-group-type="author"><kwd>Antimicrobial Resistance</kwd><kwd>Multidrug-Resistant Pathogens</kwd><kwd>Nanotherapeutics</kwd><kwd>Drug Delivery</kwd></kwd-group>
</article-meta>
</front>
<back><ref-list><title>References</title>
<ref id="R1"><label>1</label><mixed-citation>Adeniji OO, Nontongana N, Okoh JC, Okoh AI. The potential of antibiotics and nanomaterial combinations as therapeutic strategies in the management of multidrug-resistant infections: a review. Int J Mol Sci. 2022;23(23):15038. Available from: https://mdpi.com</mixed-citation></ref>
<ref id="R2"><label>2</label><mixed-citation>Adeniji OO, Ojemaye MO, Okoh AI. Antibacterial activity of metallic nanoparticles against multidrug-resistant pathogens isolated from environmental samples: nanoparticles/antibiotic combination therapy …. ACS Appl Bio Mater. 2022.</mixed-citation></ref>
<ref id="R3"><label>3</label><mixed-citation>Aparecido Dos Santos Ramos M, Bento Da Silva P, Spósito L, Gaspar De Toledo L, Vidal Bonifácio B, Fernanda Rodero C, et al. Nanotechnology-based drug delivery systems for control of microbial biofilms: a review. 2018. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R4"><label>4</label><mixed-citation>Aslam B, Asghar R, Muzammil S, Shafique M, Siddique AB, Khurshid M, et al. AMR and sustainable development goals: at a crossroads. Glob Health. 2024;20(1):73. Available from: https://springer.com</mixed-citation></ref>
<ref id="R5"><label>5</label><mixed-citation>Ayon NJ. High-throughput screening of natural product and synthetic molecule libraries for antibacterial drug discovery. Metabolites. 2023. Available from: https://mdpi.com</mixed-citation></ref>
<ref id="R6"><label>6</label><mixed-citation>Barhoum A, García-Betancourt ML, Jeevanandam J, Hussien EA, Mekkawy SA, Mostafa M, et al. Review on natural, incidental, bioinspired, and engineered nanomaterials: history, definitions, classifications, synthesis, properties, market, toxicities, risks, and regulations. Nanomaterials (Basel). 2022;12(2):177. Available from: https://mdpi.com</mixed-citation></ref>
<ref id="R7"><label>7</label><mixed-citation>Bhattacharjee S. Craft of co-encapsulation in International Journal of Medical and All Body Health Research www.allmedicaljournal.com nanomedicine: A struggle to achieve synergy through reciprocity. ACS Pharmacol Transl Sci. 2022. Available from: https://acs.org</mixed-citation></ref>
<ref id="R8"><label>8</label><mixed-citation>Chandranand PS, Nair A. Applications of artificial intelligence and machine learning models in nanotherapeutics. Nanomedicine in Translational Research. 2025.</mixed-citation></ref>
<ref id="R9"><label>9</label><mixed-citation>Desai N, Rana D, Patel M, Bajwa N, Prasad R, Vora LK. Nanoparticle therapeutics in clinical perspective: classification, marketed products, and regulatory landscape. Small. 2025. Available from: https://wiley.com</mixed-citation></ref>
<ref id="R10"><label>10</label><mixed-citation>Devi Thillai B, Kini S, Deekshit VK. Nanobiotics to tackle efflux-mediated resistance in bacterial pathogens. Crit Rev Microbiol. 2025:1-23.</mixed-citation></ref>
<ref id="R11"><label>11</label><mixed-citation>Đorđević S, Medel Gonzalez M, Conejos-Sánchez I, Carreira B, Pozzi S, C. Acúrcio R, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. 2021. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R12"><label>12</label><mixed-citation>E A de Kraker M, Sommer H, de Velde F, Gravestock I, Weiss E, McAleenan A, et al. Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper from COMBACTE’s STAT-Net. 2018.</mixed-citation></ref>
<ref id="R13"><label>13</label><mixed-citation>Elbehiry A, Abalkhail A. Antimicrobial nanoparticles against superbugs: mechanistic insights, biomedical applications, and translational frontiers. Pharmaceuticals (Basel). 2025. Available from: https://nih.gov</mixed-citation></ref>
<ref id="R14"><label>14</label><mixed-citation>Elitaş M. On-chip isoniazid exposure of mycobacterium smegmatis penicillin-binding protein (PBP) mutant using time-lapse fluorescent microscopy. 2018.</mixed-citation></ref>
<ref id="R15"><label>15</label><mixed-citation>Elshobary ME, Badawy NK, Ashraf Y, Zatioun AA, Masriya HH, Ammar MM, et al. Combating antibiotic resistance: mechanisms, multidrug-resistant pathogens, and novel therapeutic approaches: an updated review. Pharmaceuticals (Basel). 2025;18(3):402. Available from: https://mdpi.com</mixed-citation></ref>
<ref id="R16"><label>16</label><mixed-citation>Ferreres G, Ivanova K, Ivanov I, Tzanov T. Nanomaterials and Coatings for Managing Antibiotic-Resistant Biofilms. 2023. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R17"><label>17</label><mixed-citation>Goel N, Hashmi Z, Khan N, Ahmad R, Khan WH. Recent strategies to combat multidrug resistance. In: Non-traditional approaches to combat antimicrobial drug resistance. Singapore: Springer Nature Singapore; 2023. p. 1-27.</mixed-citation></ref>
<ref id="R18"><label>18</label><mixed-citation>Hao JN, Ge K, Chen G, Dai B, Li Y. Strategies to engineer various nanocarrier-based hybrid catalysts for enhanced chemodynamic cancer therapy. Chem Soc Rev. 2023.</mixed-citation></ref>
<ref id="R19"><label>19</label><mixed-citation>Hua S, B. C. de Matos M, M. Metselaar J, Storm G. Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization. 2018. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R20"><label>20</label><mixed-citation>Hueppe N, Wurm FR, Landfester K. Nanocarriers with multiple cargo load—A comprehensive preparation guideline using orthogonal strategies. Macromol Rapid Commun. 2023;44(16):2200611. Available from: https://wiley.com</mixed-citation></ref>
<ref id="R21"><label>21</label><mixed-citation>Ramos T, A. Villacis-Aguirre C, V. López-Aguilar K, Santiago Padilla L, Altamirano C, R. Toledo J, et al. The Hitchhiker’s Guide to Human Therapeutic Nanoparticle Development. 2022. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R22"><label>22</label><mixed-citation>Imran M, Kumar Jha S, Hasan N, Insaf A, Shrestha J, Shrestha J, et al. Overcoming Multidrug Resistance of Antibiotics via Nanodelivery Systems. 2022. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R23"><label>23</label><mixed-citation>Karnwal A, Kumar G, Pant G, Hossain K, Ahmad A, Alshammari MB. Perspectives on usage of functional nanomaterials in antimicrobial therapy for antibiotic-resistant bacterial infections. ACS Omega. 2023;8(15):13492-13508. Available f rom: https://acs.org</mixed-citation></ref>
<ref id="R24"><label>24</label><mixed-citation>Kavishka Jayasinghe M, Yu Lee C, T. T. Tran T, Tan R, Min Chew S, Zhi Jie Yeo B, et al. The Role of in silico Research in Developing Nanoparticle -Based Therapeutics. 2022. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R25"><label>25</label><mixed-citation>Korsmeyer R. Critical questions in development of targeted nanoparticle therapeutics. 2016. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R26"><label>26</label><mixed-citation>Lotola Mougeni F, Bofill Roig M, Hübner MP, Klarmann-Schulz U, Lenz B, Specht S, et al. Design and analysis of randomized clinical trials for onchocerciasis, loiasis and mansonellosis: A systematic review. PLoS Negl Trop Dis. 2026;20(2):e0013992. Available from: https://plos.org</mixed-citation></ref>
<ref id="R27"><label>27</label><mixed-citation>Mishra M, Kumar S, K. Majhi R, Goswami L, Goswami C, Mohapatra H. Antibacterial Efficacy of Polysaccharide Capped Silver Nanoparticles Is Not Compromised by AcrAB-TolC Efflux Pump. 2018. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R28"><label>28</label><mixed-citation>Mishra S, Gupta A, Upadhye V, Singh SC, Sinha RP, Häder DP. Therapeutic strategies against biofilm infections. Life (Basel). 2023;13(1):172. Available from: https://mdpi.com</mixed-citation></ref>
<ref id="R29"><label>29</label><mixed-citation>Nikoletic A, Natsaridis E, Flathmann T, Quadros DP, Gogniat N, Tagit O. Soft nanocarriers as antimicrobial co‐delivery systems to combat resistant infections. Adv Healthc Mater. 2025;14(21):2404540. Available from: https://wiley.com</mixed-citation></ref>
<ref id="R30"><label>30</label><mixed-citation>Parmanik A, Das S, Kar B, Bose A, Dwivedi GR, Pandey MM. Current treatment strategies against multidrug-resistant bacteria: a review. Curr Microbiol. 2022;79(12):388. Available from: https://nih.gov</mixed-citation></ref>
<ref id="R31"><label>31</label><mixed-citation>Pothineni BK, Keller A. Nanoparticle‐based formulations of glycopeptide antibiotics: a means for overcoming vancomycin resistance in bacterial pathogens? Adv NanoBiomed Res. 2023. Available from: https://wiley.com</mixed-citation></ref>
<ref id="R32"><label>32</label><mixed-citation>Rao H, Choo S, Raja Rajeswari Mahalingam S, Sekar Adisuri D, Madhavan P, Md. Akim A, et al. Approaches for Mitigating Microbial Biofilm-Related Drug Resistance: A Focus on Micro- and Nanotechnologies. 2021. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R33"><label>33</label><mixed-citation>Ruden S, Rieder A, Chis Ster I, Schwartz T, Mikut R, Hilpert K. Synergy Pattern of Short Cationic Antimicrobial Peptides Against Multidrug-Resistant Pseudomonas aeruginosa. 2019.</mixed-citation></ref>
<ref id="R34"><label>34</label><mixed-citation>Sahli C, Moya SE, Lomas JS, Gravier-Pelletier C, Briandet R, Hémadi M. Recent advances in nanotechnology for eradicating bacterial biofilm. Theranostics. 2022;12(5):2383. Available from: https://nih.gov</mixed-citation></ref>
<ref id="R35"><label>35</label><mixed-citation>Skłodowski K, Joanna Chmielewska-Deptuła S, Piktel International Journal of Medical and All Body Health Research www.allmedicaljournal.com E, Wolak P, Wollny T, Bucki R. Metallic Nanosystems in the Development of Antimicrobial Strategies with High Antimicrobial Activity and High Biocompatibility. 2023. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R36"><label>36</label><mixed-citation>Soclo Dansi SE, Degbey CC, Kpozehouen A, Gaffan N, Agbokou AD, Tapha O, et al. Stability and efficacy of chlorinated disinfectants in beninese hospitals: issues for the prevention and control of infections and antibiotic resistance. Trop Med Infect Dis. 2025;11(1):12. Available from: https://mdpi.com</mixed-citation></ref>
<ref id="R37"><label>37</label><mixed-citation>Vukomanovic M, Torrents E. High time resolution and high signal-to-noise monitoring of the bacterial growth kinetics in the presence of plasmonic nanoparticles. 2019. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R38"><label>38</label><mixed-citation>W. T. Yates J, A Fairman D. How translational modeling in oncology needs to get the mechanism just right. 2021. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R39"><label>39</label><mixed-citation>Wang L, Hu D, Xu J, Hu J, Wang Y. Complex in vitro model: A transformative model in drug development and precision medicine. Clin Transl Sci. 2024;17(2):e13695. Available from: https://wiley.com</mixed-citation></ref>
<ref id="R40"><label>40</label><mixed-citation>Wei X, Guo J, Geng X, Chen Y, Wei X, Liu B, et al. Unleashing the power of precision drug delivery: Genetically engineered biomimetic nanodrugs incorporating liposomal polypharmacy against multidrug-resistant bacteria. Chem Eng J. 2024;497:154515.</mixed-citation></ref>
<ref id="R41"><label>41</label><mixed-citation>Wong AA, Baker SE, Duoss EB, Resch M, Sick V. Science of Scale-Up: Accelerating chemical manufacturing technology development workshop report. 2025. Available from: https://osti.gov</mixed-citation></ref>
<ref id="R42"><label>42</label><mixed-citation>Xi NM, Wang L. A Two-Step Test to Identify Zero-Inflated Biomarkers in Early-Phase Clinical Trials. arXiv preprint arXiv:2508.10764. 2025.</mixed-citation></ref>
<ref id="R43"><label>43</label><mixed-citation>Yang D, Ding M, Song Y, Hu Y, Xiu W, Yuwen L, et al. Nanotherapeutics with immunoregulatory functions for the treatment of bacterial infection. 2023. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R44"><label>44</label><mixed-citation>Yang X, Ye W, Qi Y, Ying Y, Xia Z. Overcoming Multidrug Resistance in Bacteria Through Antibiotics Delivery in Surface-Engineered Nano-Cargos: Recent Developments for Future Nano-Antibiotics. 2021. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R45"><label>45</label><mixed-citation>Zhang W, Hu E, Wang Y, Miao S, Liu Y, Hu Y, et al. Emerging Antibacterial Strategies with Application of Targeting Drug Delivery System and Combined Treatment. 2021. Available from: https://ncbi.nlm.nih.gov</mixed-citation></ref>
<ref id="R46"><label>46</label><mixed-citation>Zhang Y, Lin S, Fu J, Zhang W, Shu G, Lin J, et al. Nanocarriers for combating biofilms: Advantages and challenges. J Appl Microbiol. 2022;133(3):1273-1287. Available from: https://wiley.com</mixed-citation></ref>
<ref id="R47"><label>47</label><mixed-citation>Zou W, McAdorey A, Yan H, Chen W. Nanomedicine to overcome antimicrobial resistance: Challenges and prospects. Nanomedicine (Lond). 2023. Available from: https://tandfonline.com</mixed-citation></ref>
</ref-list></back>
</article>